Trial Profile

A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects with Select Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Monalizumab (Primary) ; Bevacizumab; Cetuximab; Fluorouracil; Folinic acid; Oxaliplatin
Indications Colorectal cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors AstraZeneca; MedImmune

Most Recent Events

01 Nov 2024 Planned End Date changed from 2 Sep 2024 to 1 Sep 2025.
08 Mar 2024 This trial has been completed in Italy, according to European Clinical Trials Database record.
19 Oct 2023 Planned End Date changed from 29 Jun 2023 to 2 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com